A prediction system for the anti-tumor effect of dexrazoxane in ESCC
By combining chemotherapy dosage control, electrocardiogram and magnetic resonance detection, a prediction model of right-rezosheng's concentration was established, which solved the problem of insufficient heart protection in ESCC chemotherapy centers and achieved effective protection of the heart.
Patent Information
- Application Number
- CN202210923892.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-08-02
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-08-02
AI Technical Summary
In esophageal squamous cell carcinoma (ESCC) chemotherapy, anthracyclines lack reasonable use regulations on the prevention of toxicity of the heart, resulting in insufficient cardiac protection and existing measures cannot effectively prevent cardiac damage.
Develop an anti-tumor prediction system for derezosen. By combining chemotherapy dose control, electrocardiogram and magnetic resonance detection, a prediction model of derezosen concentration is established. Based on historical data and experimental data, it predicts its use in ESCC treatment. cardiac protection range.
It effectively avoids the risk of insufficient cardiac protection caused by irregular use of right Rezosen and ensures the cardiac protection effect in ESCC treatment.
Smart Images

Figure CN115153576B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of a riding protection device for an anti-tumor prediction system of dexrazoxane in ESCC, and in particular to an anti-tumor prediction system of dexrazoxane in ESCC. Background Art
[0002] Esophageal cancer is one of the upper gastrointestinal malignancies with the highest morbidity and mortality in the world. It ranks sixth among the causes of cancer death worldwide. The incidence and mortality of esophageal cancer in my country have remained high. Among them, 90% of esophageal cancer pathological types are esophageal squamous cell carcinoma (ESCC). Multidisciplinary comprehensive treatments such as surgery, radiotherapy, chemotherapy and targeted therapy are the main means of modern ESCC treatment, and chemotherapy is the mainstay of treatment for patients with advanced or metastatic tumors. Most of the side effects of chemotherapy drugs are relatively mild, but sometimes they can cause heart damage and weaken the myocardium, especially when administered simultaneously with anthracyclines. The risk of heart damage is greatly increased, and cardiovascular complications caused by chemotherapy are the leading non-tumor cause of death after chemotherapy for chest tumors. Therefore, heart protection is very important in the treatment of ESCC.
[0003] At present, the main measure to prevent the cardiotoxicity caused by anthracyclines is to use protective drugs. Among them, dexrazoxane is highly recognized among the effective drugs currently used to prevent anthracycline cardiotoxicity. However, due to the different physical conditions and severity of the patients, as well as the changes in chemotherapy drug dosages and the subjective judgment of doctors, there is no reasonable use standard for dexrazoxane. Once the use of dexrazoxane does not meet the requirements, there is a risk of not being able to effectively protect the heart. Therefore, how to ensure that dexrazoxane is effectively used during chemotherapy is of great significance to the protection of the heart in the treatment of ESCC. Summary of the invention
[0004] The purpose of the present invention is to provide an anti-tumor prediction system for dexrazoxane in ESCC. According to the existing medical records and patient diagnosis as a historical reference database, the dexrazoxane dosage is used as a variable, and the patient's tumor cells are extracted as experimental subjects. The dexrazoxane concentration is changed by controlling the chemotherapy dosage, and the heart damage is detected by electrocardiogram and magnetic resonance imaging. Combining historical data and experimental data, an effective dexrazoxane usage range can be predicted to establish a dexrazoxane usage prediction model, which avoids the risk of improper use of dexrazoxane failing to achieve heart protection to a certain extent, and can effectively solve the problems in the background technology.
[0005] To achieve the above object, the present invention provides the following technical solutions:
[0006] A system for predicting the anti-tumor effect of dexrazoxane in ESCC comprises a base, a bracket, a control device, a console, an electrocardiographic device, a detection probe, a magnet, a radio frequency generator, a data receiver, a shielding box, and a display screen. A bracket is arranged on one side of the base, a shielding box is arranged on the top of the base to isolate radiation, the bracket is fixedly connected to the control device, a display screen is arranged on the upper end of the bracket extending to one side, a console is arranged at the bottom of the shielding box, the console is used to control the orientation of the electrocardiographic device, the electrocardiographic device is connected to the upper part of the console, a magnet is arranged on the inner wall of the shielding box, radio frequency generators are arranged on both sides below the magnet, the radio frequency generator is used to emit pulse signals to a biological being to be detected, the data receiver is located in the middle of one side of the inner wall of the shielding box close to the bracket, under the action of the internal magnetic field, the data receiver is used to receive the detection data signal, the data receiver transmits the data signal to the control device by wireless transmission, and the processed detection result and prediction result are displayed on the display screen.
[0007] As a further solution of the present invention: the shell of the base is made of radiation-proof material, mainly because the internal inspection equipment mainly emits wireless electromagnetic signals to prevent the human body from having adverse reactions to radio wave signals. Therefore, the base also takes radiation protection into consideration when serving as a system inspection platform.
[0008] As a further solution of the present invention: the bracket is used to connect an external processing device to prevent the radio signals involved in the external device control device and the display screen from affecting the inspection results inside the shielding box, so the control device and the display screen need to maintain a certain distance from the shielding box. At the same time, in order to facilitate the observation of the results displayed on the display screen, the bracket is rotatably connected to the display screen, and the display angle of the display screen can be adjusted according to the observation direction.
[0009] As a further solution of the present invention: the control device includes a power supply and a wireless processor. The function of the power supply is to start and shut down the operation of the control device. The function of the wireless processor is to receive the wireless signal transmitted during the inspection of the internal equipment of the shielding box and process the data to transmit the result to the display screen, and the inspection result is displayed on the display screen.
[0010] As a further solution of the present invention: the console is used to control and adjust the position of the electrocardiographic sensing device. Based on the activity of the biological tissue to be tested, the detection position of the electrocardiographic sensing device on the biological tissue to be tested should not be fixed, so a console is provided to control and adjust the detection position of the electrocardiographic sensing device through the sensing position of the biological tissue to be tested. The electrocardiographic sensing device includes an electrocardiographic testing platform, electrodes, a wearing ring, wires, a temperature sensor, and a pressure sensor. The electrocardiographic testing platform is used to provide an activity platform for the biological tissue to be tested. The surface of the electrocardiographic testing platform is provided with a temperature sensor and a pressure sensor. The temperature sensor and the pressure sensor are used to detect basic vital signs of the biological tissue to be tested. The wearing ring is used to be worn on the biological tissue to be tested. A plurality of electrodes are arranged on the wearing ring to detect whether the heart rate and heartbeat of the biological tissue to be tested are in a normal state. The wearing ring is connected to the electrocardiographic testing platform through wires.
[0011] As a further solution of the present invention: based on the dual detection of cardiac toxicity of the biological tissue to be tested, magnets are arranged on both sides of the inner wall of the shielding box. The magnets are a kind of permanent magnets that are stable and not easy to change, so as to prevent the changes in the detection magnetic field environment from affecting the detection results. Therefore, it is necessary to establish a stable and not easy to change magnetic field environment. Under the stable magnetic field, the radio frequency generator transmits a pulse signal to the biological tissue to be tested. Since different magnetic resonance signals will be generated if the pericardium, myocardium, etc. are inflamed, etc. inside the heart, the resonance signal is received by the data receiver.
[0012] As a further solution of the present invention: in order to prevent the internal detection instruments from causing adverse radiation effects on the detection personnel, a shielding box is set to isolate the detection environment and also prevent the operation of external instruments from affecting the internal magnetic field environment to ensure the accuracy of the detection data. Since the material of the shielding box is generally an opaque material, a detection probe is provided on the inner wall of the shielding box. The detection probe is used for real-time monitoring of the biological tissue to be tested so that the detection personnel can promptly detect abnormalities in the biological tissue to be tested.
[0013] As a further solution of the present invention, a system for predicting the anti-tumor effect of dexrazoxane in ESCC includes the following detection method:
[0014] Step 1: Inject the extracted ESCC tumor cells into the biological tissue to be tested, classify the ESCC tumor grade according to the degree of tumor cell diffusion in the biological tissue, and then test the biological tissue in groups;
[0015] Step 2: Change the concentration of dexrazoxane by controlling the dosage of chemotherapy drugs, inject chemotherapy drugs and dexrazoxane into the biological tissue to be tested according to medical specifications, and make a preliminary judgment on the degree of heart damage of the biological tissue to be tested based on electrocardiogram detection of the biological tissue to be tested;
[0016] Step 3: Based on imaging processing means, the cardiac impact of the biological tissue to be tested is processed by nuclear magnetic resonance using the different vibrations under different degrees of damage to the cardiac diastolic function, and the degree of ventricular damage of the biological tissue to be tested is obtained from the image;
[0017] Step 4: Based on the historical data recorded in the control device, the concentration of dexrazoxane used in the past is compared with the concentration currently used for testing to detect the degree of cardiac damage of the tissue to be tested, and the applicable scope of dexrazoxane can be obtained according to the degree of cardiac damage obtained by the test;
[0018] Step 5: By conducting a double preliminary examination of the degree of cardiac damage of the biological tissue to be tested and comparing it with previous historical data, the effectiveness of using dexrazoxane can be determined based on a computer algorithm, and the predicted results can be reported on the display screen.
[0019] As a further embodiment of the present invention, a method for using a system for predicting the anti-tumor effect of dexrazoxane in ESCC comprises the following steps:
[0020] A: The extracted ESCC tumor cells are injected into the biological tissue to be tested. The ESCC tumor grade is divided according to the degree of tumor cell diffusion in the biological tissue, and then the biological tissue is tested in groups. The concentration of dexrazoxane is changed by controlling the dosage of chemotherapy drugs. The chemotherapy drugs and dexrazoxane are injected into the biological tissue to be tested according to medical specifications. The biological tissue to be tested that has been injected with chemotherapy drugs and dexrazoxane is placed in a shielding box, and an electrocardiographic sensing device is worn on the biological tissue to be tested. Based on the electrocardiographic detection of the biological tissue to be tested, a preliminary judgment is made on the degree of heart damage of the biological tissue to be tested. The electrocardiographic sensing device includes an electrocardiographic testing platform, an electrode sheet, a wearing ring, wires, a temperature sensor, a pressure sensor, and an electrocardiographic testing device. The platform is used to provide an activity platform for the biological tissue to be tested. The surface of the ECG test platform is provided with temperature sensors and pressure sensors, which are used to detect basic vital signs of the biological tissue to be tested. The wearing ring is worn on the biological tissue to be tested in a buckle connection manner. A number of electrodes are arranged on the wearing ring to detect whether the heart rate and heartbeat of the biological tissue to be tested are in a normal state. The wearing ring is connected to the ECG test platform through wires. Since the biological tissue to be tested is in an active state and constantly moves, it is necessary to adjust the detection position of the ECG sensing device, so a console is provided for controlling and adjusting the position of the ECG sensing device, and the plane movement of the ECG test platform is further adjusted by controlling the rotating shaft inside the console;
[0021] B: After placing the biological tissue to be tested in the test environment, check whether the connections of each device are unobstructed to prevent detection deviation caused by device disconnection. Since the internal inspection equipment mainly transmits wireless electromagnetic signals, the base should be used as a system inspection platform to prevent the human body from having adverse reactions to radio wave signals. The bracket is used to connect the external processing device to prevent the radio signals involved in the external device control device and the display screen from affecting the internal inspection results of the shielding box. Therefore, the control device and the display screen need to be kept at a certain distance from the shielding box. At the same time, in order to facilitate the observation of the display results, the bracket is rotatably connected to the display screen, and the display angle of the display screen can be adjusted according to the observation direction. After the safety inspection of the device is completed, turn on the power switch of the control device, and first detect the electrocardiogram of the biological tissue to be tested. Changes. If abnormal heart rate changes such as arrhythmia and sinus rhythm occur during drug use, further testing will be conducted on the heart damage of the biological tissue to be tested. Based on imaging processing methods, the different vibrations under different degrees of damage to the cardiac diastolic function will be used to process the heart of the biological tissue to be tested. The degree of ventricular damage to the biological tissue to be tested is obtained from the image. In order to prevent the internal testing instruments from causing adverse radiation effects on the testers, a shielding box is set up to isolate the test environment and prevent the operation of external instruments from affecting the internal magnetic field environment to ensure the accuracy of the test data. Since the material of the shielding box is generally opaque, a detection probe is set on the inner wall of the shielding box. The detection probe is used for real-time monitoring of the biological tissue to be tested, so that the testers can find abnormalities of the biological tissue to be tested in time;
[0022] C: Further testing is performed on the biological tissue to be tested that has unstable ECG. Magnets are arranged on both sides of the inner wall of the shielding box. The magnet is a stable permanent magnet that is not easy to change. This prevents changes in the detection magnetic field environment from affecting the detection results. Therefore, a stable magnetic field environment that is not easy to change is required. Under a stable magnetic field, the radio frequency generator transmits a pulse signal to the biological tissue to be tested. If the heart is damaged by pericardial inflammation or myocardial inflammation, different magnetic resonance signals will be generated. Therefore, the resonance signal is received by the data receiver. The data receiver transmits the data signal to the control device through wireless transmission. Based on the historical data recorded by the wireless processor in the control device, the previous concentration of dexrazoxane used is compared with the current concentration used for testing to detect the degree of cardiac damage to the tissue to be tested. The applicable scope of dexrazoxane can be obtained based on the degree of cardiac damage obtained by the test. By performing a double pre-test on the degree of cardiac damage of the biological tissue to be tested and comparing with previous historical data, the effectiveness of dexrazoxane can be determined based on a computer algorithm. The processed test results and predicted results are displayed on the display screen.
[0023] Compared with the prior art, the present invention has the following beneficial effects:
[0024] Based on the existing medical records and patient diagnosis as a historical reference database, the dosage of dexrazoxane was used as a variable, and the patient's tumor cells were extracted as experimental subjects. The concentration of dexrazoxane was changed by controlling the dosage of chemotherapy drugs, and electrocardiogram and magnetic resonance imaging were used to detect heart damage. Combining historical data with experimental data, an effective range of dexrazoxane use can be predicted to establish a dexrazoxane use prediction model, which to a certain extent avoids the risk of improper use of dexrazoxane that fails to provide heart protection. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0026] Figure 1 A schematic diagram of the side elevation structure of a prediction system for the anti-tumor effect of dexrazoxane in ESCC;
[0027] Figure 2 A schematic diagram of the front elevation structure of a system for predicting the anti-tumor effect of dexrazoxane in ESCC;
[0028] Figure 3 A schematic diagram of the structure of a central electric induction device for a prediction system of the anti-tumor effect of dexrazoxane in ESCC;
[0029] Figure 4 Schematic diagram of a detection method for the anti-tumor prediction system of dexrazoxane in ESCC.
[0030] In the figure: 1. base; 2. bracket; 3. control device; 4. control console; 5. electrocardiographic induction device; 6. detection probe; 7. magnet; 8. radio frequency generator; 9. data receiver; 10. shielding box; 11. display screen; 51. electrocardiographic testing platform; 52. electrode sheet; 53. wearing ring; 54. wire; 55. temperature sensor; 56. pressure sensor. DETAILED DESCRIPTION
[0031] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0032] Example:
[0033] See also Figure 1-Figure 4In an embodiment of the present invention, a system for predicting the anti-tumor effect of dexrazoxane in ESCC comprises a base (1), a bracket (2), a control device (3), a console (4), an electrocardiographic induction device (5), a detection probe (6), a magnet (7), a radio frequency generator (8), a data receiver (9), a shielding box (10), and a display screen (11). The base (1) is provided with a bracket (2) on one side, a shielding box (10) for isolating radiation is provided above the base (1), the bracket (2) is fixedly connected with the control device (3), a display screen (11) is provided on the upper end of the bracket (2) extending to one side, a console (4) is provided at the bottom of the shielding box (10), and the console (4) ) is used to control the orientation of the electrocardiographic induction device (5), the electrocardiographic induction device (5) is connected to the upper part of the console (4), the inner wall of the shielding box (10) is provided with a magnet (7), and radio frequency generators (8) are provided on both sides below the magnet (7), and the radio frequency generator (8) is used to transmit pulse signals to the biological being to be tested, and the data receiver (9) is located in the middle of one side of the inner wall of the shielding box (10) close to the bracket (2). Under the action of the internal magnetic field, the data receiver (9) is used to receive the detection data signal, and the data receiver (9) transmits the data signal to the control device (3) by wireless transmission, and the processed detection result and prediction result are displayed on the display screen (11).
[0034] The present invention provides an anti-tumor prediction system for dexrazoxane in ESCC, comprising the following detection method:
[0035] Step 1: Inject the extracted ESCC tumor cells into the biological tissue to be tested, classify the ESCC tumor grade according to the degree of tumor cell diffusion in the biological tissue, and then test the biological tissue in groups;
[0036] Step 2: Change the concentration of dexrazoxane by controlling the dosage of chemotherapy drugs, inject chemotherapy drugs and dexrazoxane into the biological tissue to be tested according to medical specifications, and make a preliminary judgment on the degree of heart damage of the biological tissue to be tested based on electrocardiogram detection of the biological tissue to be tested;
[0037] Step 3: Based on imaging processing means, the cardiac impact of the biological tissue to be tested is processed by nuclear magnetic resonance using the different vibrations under different degrees of damage to the cardiac diastolic function, and the degree of ventricular damage of the biological tissue to be tested is obtained from the image;
[0038] Step 4: Based on the historical data recorded in the control device, the concentration of dexrazoxane used in the past is compared with the concentration currently used for testing to detect the degree of cardiac damage of the tissue to be tested, and the applicable scope of dexrazoxane can be obtained according to the degree of cardiac damage obtained by the test;
[0039] Step 5: By conducting a double preliminary examination of the degree of cardiac damage of the biological tissue to be tested and comparing it with previous historical data, the effectiveness of using dexrazoxane can be determined based on a computer algorithm, and the predicted results can be reported on the display screen.
[0040] like Figure 1-Figure 4 The present invention also provides a method for using a system for predicting the anti-tumor effect of dexrazoxane in ESCC, wherein the specific steps are as follows:
[0041] A: Inject the extracted ESCC tumor cells into the biological tissue to be tested, classify the ESCC tumor grade according to the degree of tumor cell diffusion in the biological tissue, and then test the biological tissue in groups, change the concentration of dexrazoxane by controlling the dosage of chemotherapy drugs, inject the chemotherapy drugs and dexrazoxane into the biological tissue to be tested according to medical specifications, place the biological tissue to be tested that has been injected with chemotherapy drugs and dexrazoxane in a shielding box (10), and wear an electrocardiogram sensing device (5) on the biological tissue to be tested, and make a preliminary judgment on the degree of heart damage of the biological tissue to be tested based on electrocardiogram detection of the biological tissue to be tested, wherein the electrocardiogram sensing device (5) includes an electrocardiogram testing platform (51), an electrode sheet (52), a wearing ring (53), an electric wire (54), a temperature sensor (55), and a pressure sensor (56). The electrocardiogram testing platform (51) is used to provide the biological tissue to be tested with a temperature sensor (55). The surface of the electrocardiogram inspection platform (51) is provided with a temperature sensor (55) and a pressure sensor (56), and the temperature sensor (55) and the pressure sensor (56) are used to detect the basic vital signs of the biological tissue to be tested. The wearing ring (53) is worn on the biological tissue to be tested by a buckle connection method. The wearing ring (53) is provided with a plurality of electrode sheets (52) for detecting whether the heart rate and heartbeat of the biological tissue to be tested are in a normal state. The wearing ring (53) is connected to the electrocardiogram inspection platform (51) through an electric wire (54). Since the biological tissue to be tested is in an active state and moves continuously, it is necessary to adjust the detection position of the electrocardiogram sensing device (5). Therefore, a control console (4) is provided for controlling and adjusting the position of the electrocardiogram sensing device (5). The control console (4) further adjusts the plane movement of the electrocardiogram inspection platform (51) by controlling the rotating shaft inside.
[0042] B: After the biological tissue to be tested is placed in the test environment, check whether the connections of various devices are smooth to prevent detection deviation caused by device disconnection. Since the internal inspection equipment mainly emits radio electromagnetic signals, the human body is prevented from having adverse reactions to radio wave signals. Therefore, the base (1) is used as a system inspection platform and also has a radiation protection function. The bracket (2) is used to connect the external processing device to prevent the radio signals involved in the external device control device (3) and the display screen (11) from affecting the internal inspection results of the shielding box (10). Therefore, the control device (3) and the display screen (11) need to maintain a certain distance from the shielding box (10). At the same time, in order to facilitate the display of the results on the display screen (11) to be easy to observe, the bracket (2) is rotatably connected to the display screen (11), and the display angle of the display screen (11) can be adjusted according to the observation direction. After the safety inspection of the device is completed, turn on the power switch of the control device (3). First, the electrocardiogram changes of the biological tissue to be tested are detected. If abnormal heart rate changes such as arrhythmia and sinus rhythm occur during the use of the drug, the heart damage of the biological tissue to be tested will be further detected. Based on imaging processing methods, the heart effect of the biological tissue to be tested is processed by nuclear magnetic resonance using different vibrations under different degrees of damage to the cardiac diastolic function, and the degree of ventricular damage of the biological tissue to be tested is obtained from the image. In order to prevent the internal detection instrument from causing adverse radiation effects on the detection personnel, a shielding box (10) is set to isolate the detection environment and also prevent the operation of external instruments from affecting the internal magnetic field environment to ensure the accuracy of the detection data. Since the material of the shielding box (10) is generally an opaque material, a detection probe (6) is set on the inner wall of the shielding box (10). The detection probe (6) is used for real-time monitoring of the biological tissue to be tested so that the detection personnel can find abnormalities of the biological tissue to be tested in time;
[0043] C: Further testing is performed on the biological tissue to be tested that has ECG instability. Magnets (7) are arranged on both sides of the inner wall of the shielding box (10). The magnets (7) are stable permanent magnets that are not easily changed. The magnets (7) are used to prevent changes in the detection magnetic field environment from affecting the detection results. Therefore, a stable magnetic field environment that is not easily changed is required. Under the stable magnetic field, the radio frequency generator (8) transmits a pulse signal to the biological tissue to be tested. Since different magnetic resonance signals will be generated if the heart is damaged by inflammation of the pericardium or myocardium, the resonance signal is received by the data receiver (9). The data receiver (9) transmits the data signal to the control device (3) by wireless transmission. Based on the historical data recorded by the wireless processor in the control device, the concentration of dexrazoxane used in the past and the concentration used in the current test are compared to detect the degree of cardiac damage of the tissue to be tested. The applicable scope of dexrazoxane can be obtained based on the degree of cardiac damage obtained by the test. By performing a double pre-test on the degree of cardiac damage of the biological tissue to be tested and comparing and referring to the historical data in the past, the use benefit of dexrazoxane can be determined based on the computer algorithm. The processed test results and predicted results are displayed on the display screen (11).
[0044] The working principle of the present invention is: based on the existing medical records and patient diagnosis as a historical reference database, the dosage of dexrazoxane is used as a variable, and the patient's tumor cells are extracted as experimental objects. The dexrazoxane concentration is changed by controlling the chemotherapy dosage, and the heart damage is detected by electrocardiogram and magnetic resonance imaging. Combining historical data and experimental data, an effective dexrazoxane usage range can be predicted to establish a dexrazoxane usage prediction model, which avoids the risk of improper use of dexrazoxane failing to achieve heart protection to a certain extent.
[0045] What is described above is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
Claims
1. A system for predicting the anti-tumor effect of dexrazoxane in ESCC, characterized in that: The invention comprises a base (1), a bracket (2), a control device (3), a console (4), an electrocardiographic device (5), a detection probe (6), a magnet (7), a radio frequency generator (8), a data receiver (9), a shielding box (10), and a display screen (11). The base (1) is provided with a bracket (2) on one side, a shielding box (10) for isolating radiation is provided above the base (1), the bracket (2) is fixedly connected with the control device (3), the upper end of the bracket (2) is extended to one side and provided with a display screen (11), the bottom of the shielding box (10) is provided with a console (4), the console (4) is used to control the orientation of the electrocardiographic device (5), and the electrocardiographic device (5) is provided with a control device (3). The device (5) is connected to the upper part of the console (4), the inner wall of the shielding box (10) is provided with a magnet (7), and radio frequency generators (8) are provided on both sides below the magnet (7), and the radio frequency generators (8) are used to emit pulse signals to the biological being to be tested, and the data receiver (9) is located in the middle of one side of the inner wall of the shielding box (10) close to the bracket (2). Under the action of the internal magnetic field, the data receiver (9) is used to receive the detection data signal, and the data receiver (9) transmits the data signal to the control device (3) by wireless transmission, and the processed detection result and prediction result are displayed on the display screen (11); the detection method includes the following: Step 1: Inject the extracted ESCC tumor cells into the biological tissue to be tested, classify the ESCC tumor grade according to the degree of tumor cell diffusion in the biological tissue, and then test the biological tissue in groups; Step 2: Change the concentration of dexrazoxane by controlling the dosage of chemotherapy drugs, inject chemotherapy drugs and dexrazoxane into the biological tissue to be tested according to medical specifications, and make a preliminary judgment on the degree of heart damage of the biological tissue to be tested based on electrocardiogram detection of the biological tissue to be tested; Step 3: Based on imaging processing means, the cardiac impact of the biological tissue to be tested is processed by nuclear magnetic resonance using the different vibrations under different degrees of damage to the cardiac diastolic function, and the degree of ventricular damage of the biological tissue to be tested is obtained from the image; Step 4: Based on the historical data recorded in the control device, the concentration of dexrazoxane used in the past is compared with the concentration currently used for testing to detect the degree of cardiac damage of the tissue to be tested, and the applicable scope of dexrazoxane is obtained according to the degree of cardiac damage obtained by the test; Step 5: By conducting a double preliminary examination of the degree of cardiac damage of the biological tissue to be tested and comparing it with historical data, the effectiveness of using dexrazoxane is determined based on a computer algorithm, and the predicted results are reported on the display screen.
2. The anti-tumor prediction system for dexrazoxane in ESCC according to claim 1, characterized in that: The shell of the base (1) is made of radiation-proof material, mainly because the internal inspection equipment mainly emits radio electromagnetic signals to prevent the human body from having adverse reactions to the radio wave signals. Therefore, when the base (1) is used as a system inspection platform, it also takes into account the radiation protection function.
3. The anti-tumor prediction system for dexrazoxane in ESCC according to claim 1, characterized in that: The bracket (2) is used to connect an external processing device to prevent the radio signals involved in the external device control device (3) and the display screen (11) from affecting the internal inspection results of the shielding box (10). Therefore, the control device (3) and the display screen (11) need to maintain a certain distance from the shielding box (10). At the same time, in order to facilitate the observation of the results displayed on the display screen (11), the bracket (2) is rotatably connected to the display screen (11) to adjust the display angle of the display screen (11) according to the observation direction.
4. The anti-tumor prediction system for dexrazoxane in ESCC according to claim 1, characterized in that: The control device (3) comprises a power supply and a wireless processor. The power supply is used to start and shut down the operation of the control device (3). The wireless processor is used to receive wireless signals transmitted during the inspection of the internal equipment of the shielding box (10) and process the data to transmit the results to the display screen (11), and the display screen (11) displays the inspection results.
5. The anti-tumor prediction system for dexrazoxane in ESCC according to claim 1, characterized in that: The console (4) is used to control and adjust the position of the electrocardiographic sensing device (5). Due to the activity of the biological tissue to be tested, the detection position of the electrocardiographic sensing device (5) on the biological tissue to be tested should not be fixed. Therefore, a console (4) is provided to control and adjust the detection position of the electrocardiographic sensing device (5) through the sensing position of the biological tissue to be tested. The electrocardiographic sensing device (5) comprises an electrocardiographic testing platform (51), an electrode sheet (52), a wearing ring (53), an electric wire (54), a temperature sensor (55), and a pressure sensor (56). The electrocardiographic testing platform (51) is used to A movable platform for a biological tissue to be tested is provided. A temperature sensor (55) and a pressure sensor (56) are arranged on the surface of the electrocardiogram testing platform (51). The temperature sensor (55) and the pressure sensor (56) are used to detect basic vital signs of the biological tissue to be tested. The wearing ring (53) is used to be worn on the biological tissue to be tested. A plurality of electrode sheets (52) are arranged on the wearing ring (53) to detect whether the heart rate and heartbeat of the biological tissue to be tested are in a normal state. The wearing ring (53) is connected to the electrocardiogram testing platform (51) via an electric wire (54).
6. The anti-tumor prediction system for dexrazoxane in ESCC according to claim 1, characterized in that: Based on the dual detection of cardiac toxicity of the biological tissue to be tested, magnets (7) are arranged on both sides of the inner wall of the shielding box (10). The magnets (7) are stable permanent magnets that are not easy to change, so as to prevent the change of the detection magnetic field environment from affecting the detection result. Therefore, it is necessary to establish a stable magnetic field environment that is not easy to change. Under the stable magnetic field, the radio frequency generator (8) transmits a pulse signal to the biological tissue to be tested. Since different magnetic resonance signals will be generated if the pericardium or myocardium is inflamed and damaged inside the heart, the resonance signal is received by the data receiver (9).
7. The anti-tumor prediction system for dexrazoxane in ESCC according to claim 1, characterized in that: In order to prevent the internal detection instruments from causing adverse radiation effects on the detection personnel, a shielding box (10) is provided to isolate the detection environment and also to prevent the operation of the external instruments from affecting the internal magnetic field environment so as to ensure the accuracy of the detection data. Since the material of the shielding box (10) is an opaque material, a detection probe (6) is provided on the inner wall of the shielding box (10). The detection probe (6) is used for real-time monitoring of the biological tissue to be detected so that the detection personnel can promptly discover abnormalities in the biological tissue to be detected.
Citation Information
Patent Citations
Method for predicting influence of medicine on cardiotoxicity and electrocardiogram equipment
CN114642402A
Method for the treatment of cardiotoxicity induced by antitumor compounds
US20030096823A1
